Objective:To compare the clinical efficacy and effects on cognitive function of magnetic seizure therapy (MST) and modified electroconvulsive therapy (MECT) in the treatment of major depressive episode (MDE).Methods:From January 1, 2019 to December 31, 2021, 40 patients who met the MDE diagnostic criteria in the fifth edition of the Diagnostic Statistical Manual of Mental Disorders (DSM-5) were selected in Shanghai Mental Health Center. Participants were randomly assigned to MECT therapy group (20 patients) and MST therapy group (20 patients) using the random number table method. Both groups received MECT or MST while using serotonin reuptake inhibitors (SSRIs), 3 times a week for 4 weeks. The 17-items Hamilton Depression Rating Scale (HAMD 17) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) were performed before and after treatment. HAMD 17 reduction rate and effective rate were the main assessment indicators, while RBANS total score and factor scores were considered as the secondary assessment indicators. T-test was used to compare the reduction rate of HAMD 17 between the two groups, and corrected Chi-square test or Fisher′s exact probability method was used to compare the effective rate of treatment between the two groups. HAMD 17 scores and RBANS scores before and after treatment were compared using two-factor repeated measure ANOVA. Results:There were no significant differences in baseline HAMD 17 scores and RBANS scores between 2 groups( t=0.29, P=0.773; t=0.67, P=0.509). The treatment effective rate in the MECT group was 90% (18/20), and the average reduction rate of HAMD 17 was 67.9%. Meanwhile, the effective rate of MST group was 75% (15/20), and the average reduction rate of HAMD 17 was 60.9%. There was no significant difference in the reduction rate and effective rate of HAMD 17 between the two groups ( t=0.69, P=0.493; χ2=0.16, P=0.693). The total scores and factor scores of RBANS after treatment were lower than those before treatment, with statistical significance(total scores: F=19.29, P<0.001;immediate memory score: F=6.22, P=0.020; language function score: F=9.13, P=0.006;attention score: F=5.23, P=0.031;delayed memory score: F=35.90, P<0.001). There was no significant difference in the total scores and factor scores of RBANS before and after treatment in MST group(total scores: F=0.49, P=0.490;immediate memory score: F=2.25, P=0.147;language function score: F=1.22, P=0.280;attention score: F=0.23, P=0.640;delayed memory score: F=0.02, P=0.887). Conclusions:The efficacy of MST treatment and MECT treatment in treating MDE patients seems to be comparable. MDE patients receiving MST had less impact on cognitive function compared to those treated with MECT.

Objective:To compare the clinical efficacy and effects on cognitive function of magnetic seizure therapy (MST) and modified electroconvulsive therapy (MECT) in the treatment of major depressive episode (MDE).Methods:From January 1, 2019 to December 31, 2021, 40 patients who met the MDE diagnostic criteria in the fifth edition of the Diagnostic Statistical Manual of Mental Disorders (DSM-5) were selected in Shanghai Mental Health Center. Participants were randomly assigned to MECT therapy group (20 patients) and MST therapy group (20 patients) using the random number table method. Both groups received MECT or MST while using serotonin reuptake inhibitors (SSRIs), 3 times a week for 4 weeks. The 17-items Hamilton Depression Rating Scale (HAMD 17) and the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) were performed before and after treatment. HAMD 17 reduction rate and effective rate were the main assessment indicators, while RBANS total score and factor scores were considered as the secondary assessment indicators. T-test was used to compare the reduction rate of HAMD 17 between the two groups, and corrected Chi-square test or Fisher′s exact probability method was used to compare the effective rate of treatment between the two groups. HAMD 17 scores and RBANS scores before and after treatment were compared using two-factor repeated measure ANOVA. Results:There were no significant differences in baseline HAMD 17 scores and RBANS scores between 2 groups( t=0.29, P=0.773; t=0.67, P=0.509). The treatment effective rate in the MECT group was 90% (18/20), and the average reduction rate of HAMD 17 was 67.9%. Meanwhile, the effective rate of MST group was 75% (15/20), and the average reduction rate of HAMD 17 was 60.9%. There was no significant difference in the reduction rate and effective rate of HAMD 17 between the two groups ( t=0.69, P=0.493; χ2=0.16, P=0.693). The total scores and factor scores of RBANS after treatment were lower than those before treatment, with statistical significance(total scores: F=19.29, P<0.001;immediate memory score: F=6.22, P=0.020; language function score: F=9.13, P=0.006;attention score: F=5.23, P=0.031;delayed memory score: F=35.90, P<0.001). There was no significant difference in the total scores and factor scores of RBANS before and after treatment in MST group(total scores: F=0.49, P=0.490;immediate memory score: F=2.25, P=0.147;language function score: F=1.22, P=0.280;attention score: F=0.23, P=0.640;delayed memory score: F=0.02, P=0.887). Conclusions:The efficacy of MST treatment and MECT treatment in treating MDE patients seems to be comparable. MDE patients receiving MST had less impact on cognitive function compared to those treated with MECT.

Objective To investigate the feasibility and clinical effect of tranexamic acid in prehospital emergency care of patients with craniocerebral trauma.Methods A randomized,placebo controlled trial was carried out on 77 craniocerebral trauma patients [Glasgow Coma Scale (GCS) ≤12 points]enrolled between May 2015 and December 2016.There were 45 males and 32 females,with an average age of 36.5 years (range,19-73 years).Among the patients,37 cases were caused by traffic accidents,19 falling from high places,11 falling when walking,and ten by being hit.According to the random number table method,they were divided into control group (39 cases) and treatment group (38 cases).The treatment group received 1 g of tranexamic acid by intravenous injection within ten minutes on the scene and another 1 g of tranexamic acid within eight hours at the hospital.The control group received 0.9％ isotonic saline.The operation and medication followed the routine process.The arrival time of ambulance and the time of first medication use were recorded.The plasma fibrin degradation products (FDP) and D-dimer at admission and 1 d post-trauma,the percentage of cranitomy operation,case fatality rate,red blood cell transfusion,length of stay in the neurosurgical intensive care unit (NICU),and the Glasgow Outcome Scale (GOS) at day 28 were all recorded and analyzed.Results No significant differences were found between the two groups in gender,age,injury causes,GCS,arrival time of ambulance,and the time of first medication use (P ＞ 0.05).The FDP and D-dimer at admission of the two groups were similar (P ＞ 0.05).One day after admission,the expression of plasma FDP was significantly lower in treatment group than that in control group [6758 (4732,13661) μg/L vs.11740 (8516,21756) μg/L] (P ＜ 0.01).The expression of D-dimer was significantly lower in treatment group than that in control group [1074 (849,1414) μg/L vs.1722 (1389,2330) μg/L] (P ＜ 0.01).Between group differences were insignificant in the percentage of craniotomy operation,case fatality rate,and red blood cell transfusion (P ＞ 0.05).However,treatment group showed shorter stay in NICU [4 (1,12)days vs.2 (0,4)days] and higher GOS [4 (3,5)points vs.5 (4,5)points]than control group (both P ＜ 0.01).Conclusions Tranexamic acid can be applied conveniently in pre-hospital emergency care of craniocerebral trauma patients.It can effectively realize the synchronization of pre hospital transport and treatment,eventually reducing the time of NICU treatment as well as improving the prognosis.

Glucocorticoid receptor (GR) is identified as a member of nuclear receptor family. To exert its biological action, the ligand bound GR is translocated from the cytoplasm into the nucleus by regulating transcriptional signals of related genes. In clinical practice, the effects of glucocorticoid are often mediated by GR signaling pathways. An increasing number of studies have indicated that GR signaling pathways play an essential role in the proliferation, invasion and prognosis of bladder cancer. Meanwhile, the new-generation selective GR activator improves its anti-tumor effects, and at the same time reduces the adverse reactions of hormones, which probably raises the prospect for the treatment of bladder cancer.
Animals ; Antineoplastic Agents ; pharmacology ; Cell Nucleus ; genetics ; Humans ; Prognosis ; Protein Transport ; genetics ; Receptors, Glucocorticoid ; agonists ; physiology ; Signal Transduction ; genetics ; Transcriptional Activation ; drug effects ; physiology ; Urinary Bladder Neoplasms ; genetics ; physiopathology

Objective To explore the therapeutic effects of sub-hypothermia and hyperbaric oxygen (HBO) combined with drugs in the treatment of patients with severe traumatic brain injury in the high plateau region and possible mechanism involved.Methods With the knowledge and consent of the patients and following the approval of the ethics committee,118 patients with severe traumatic brain injury were randomly divided into the comprehensive treatment group (58 cases),the sub-hypothermia group (30 cases) and the HBO group (30 cases).Fifty-eight patients in the comprehensive treatment group had sub-hypothermia and HBO treatment,in addition to routine drug therapy; the patients in the sub-hypothermia group were treated with sub-hypothermia in addition to routine drug therapy; and the patients in the HBO groups received HBO therapy in addition to routine drug therapy.Glasgow coma scale (GCS) scores,Glasgow outcome scale (GOS) scores and therapeutic effects were closely observed and compared both before and after treatment between the 3 groups.Results Analyses indicated that total efficacy for the comprehensive treatment group was 93.16％,which was higher that of the sub-hypothermia group (66.7％) and the HBO group (76.7％),with statistical significance(P ＜ 0.05),when comparisons were made between the 3 groups.Before therapy,there were significant differences in the GCS scores for the 3 groups (P ＞ 0.05).Following treatment with respective protocols,GCS scores for the 3 groups all increased to some extent,and differences could be uoted in statistical significance,when comparisons were made between pre-therapy and post-therapy (P ＜ 0.05).Following treatment,GCS and GOS scores for the comprehensive treatment group were obviously higher than those of the sub-hypothermia group and the HBO group,and there were statistical differences when comparisons were made between the 3 groups (P ＜ 0.05).Conclusions Early application of sub-hypothermia and timely treatment with HBO could significantly improve the therapeutic effects on patients with severe traumatic brain injury,decrease mortality,reduce incidence of neural function disorder after severe traumatic brain injury and the incidence of sequelae,and at the same time could improve the life quality ofthe patients.

Objective To explore the therapeutic effects of sub-hypothermia and hyperbaric oxygen (HBO) combined with drugs in the treatment of patients with severe traumatic brain injury in the high plateau region and possible mechanism involved.Methods With the knowledge and consent of the patients and following the approval of the ethics committee,118 patients with severe traumatic brain injury were randomly divided into the comprehensive treatment group (58 cases),the sub-hypothermia group (30 cases) and the HBO group (30 cases).Fifty-eight patients in the comprehensive treatment group had sub-hypothermia and HBO treatment,in addition to routine drug therapy; the patients in the sub-hypothermia group were treated with sub-hypothermia in addition to routine drug therapy; and the patients in the HBO groups received HBO therapy in addition to routine drug therapy.Glasgow coma scale (GCS) scores,Glasgow outcome scale (GOS) scores and therapeutic effects were closely observed and compared both before and after treatment between the 3 groups.Results Analyses indicated that total efficacy for the comprehensive treatment group was 93.16％,which was higher that of the sub-hypothermia group (66.7％) and the HBO group (76.7％),with statistical significance(P ＜ 0.05),when comparisons were made between the 3 groups.Before therapy,there were significant differences in the GCS scores for the 3 groups (P ＞ 0.05).Following treatment with respective protocols,GCS scores for the 3 groups all increased to some extent,and differences could be uoted in statistical significance,when comparisons were made between pre-therapy and post-therapy (P ＜ 0.05).Following treatment,GCS and GOS scores for the comprehensive treatment group were obviously higher than those of the sub-hypothermia group and the HBO group,and there were statistical differences when comparisons were made between the 3 groups (P ＜ 0.05).Conclusions Early application of sub-hypothermia and timely treatment with HBO could significantly improve the therapeutic effects on patients with severe traumatic brain injury,decrease mortality,reduce incidence of neural function disorder after severe traumatic brain injury and the incidence of sequelae,and at the same time could improve the life quality ofthe patients.